SEC Form 4 · accession 0001209191-17-043855
Viking Therapeutics, Inc. · VKTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles A Rowland Jr.
Director
Period of report
Jul 1, 2017
Accepted (ET)
Jul 5, 2017 · 9:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001607678
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $1.08 | Jul 1, 2017 | A | 40,000 | A | Jul 1, 2018 | Jul 1, 2027 | Common Stock | 40,000 | 40,000 | D |